Cargando…
Seroprevalence of IgG Anti-SARS-CoV-2 among Voluntary Blood Donors in Dubai: Demographic and Risk Factors
BACKGROUND AND OBJECTIVES: During the pandemic of COVID-19, additional blood donor eligibility criteria have been added to ensure safety of donors and donations. The aim of this study is to estimate the seroprevalence of SARS-CoV-2 antibody in eligible donors and to study the demography and lifesty...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339022/ http://dx.doi.org/10.1159/000517456 |
_version_ | 1783733509548933120 |
---|---|
author | Raouf, May Rabeh, Mariem Kaur, Suminder Sharma, Ranjita Thottumkal, Nimmy Mohammed, Roukaya |
author_facet | Raouf, May Rabeh, Mariem Kaur, Suminder Sharma, Ranjita Thottumkal, Nimmy Mohammed, Roukaya |
author_sort | Raouf, May |
collection | PubMed |
description | BACKGROUND AND OBJECTIVES: During the pandemic of COVID-19, additional blood donor eligibility criteria have been added to ensure safety of donors and donations. The aim of this study is to estimate the seroprevalence of SARS-CoV-2 antibody in eligible donors and to study the demography and lifestyle of asymptomatic cases. MATERIALS AND METHODS: One thousand four hundred eighteen eligible donors were enrolled in this study in the Dubai Blood Donation Center from August to December 2020. Blood samples were tested for SARS-CoV-2 antibody. Donors' demographic characteristics and lifestyle were studied further. The χ<sup>2</sup> test was used to analyze the data association. RESULTS: 88.4% of the studied group were males, 85% were from age 17 to 45 years, and 53% were regular donors. The seroprevalence of SARS-CoV-2 antibody was 13.5% and significantly related to gender, frequency of donation, collection site, type of donation, and more frequent when donors shared transport and accommodation. Blood group and age had no significant association. 5.5% were found to have cough/fever or a history of contact with positive COVID-19 patients. CONCLUSIONS: The seroprevalence of SARS-CoV-2 antibody was 13.5% among eligible blood donors, and hence the current eligibility criteria allow asymptomatic COVID-19 patients to donate blood. The seroprevalence was seen more in first time donors, suggesting that regular blood donors are safer. Additional risk factors related to lifestyle can be identified to ensure safety of transfusion during COVID-19 pandemic. |
format | Online Article Text |
id | pubmed-8339022 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-83390222021-08-05 Seroprevalence of IgG Anti-SARS-CoV-2 among Voluntary Blood Donors in Dubai: Demographic and Risk Factors Raouf, May Rabeh, Mariem Kaur, Suminder Sharma, Ranjita Thottumkal, Nimmy Mohammed, Roukaya Dubai Medical Journal Research Article BACKGROUND AND OBJECTIVES: During the pandemic of COVID-19, additional blood donor eligibility criteria have been added to ensure safety of donors and donations. The aim of this study is to estimate the seroprevalence of SARS-CoV-2 antibody in eligible donors and to study the demography and lifestyle of asymptomatic cases. MATERIALS AND METHODS: One thousand four hundred eighteen eligible donors were enrolled in this study in the Dubai Blood Donation Center from August to December 2020. Blood samples were tested for SARS-CoV-2 antibody. Donors' demographic characteristics and lifestyle were studied further. The χ<sup>2</sup> test was used to analyze the data association. RESULTS: 88.4% of the studied group were males, 85% were from age 17 to 45 years, and 53% were regular donors. The seroprevalence of SARS-CoV-2 antibody was 13.5% and significantly related to gender, frequency of donation, collection site, type of donation, and more frequent when donors shared transport and accommodation. Blood group and age had no significant association. 5.5% were found to have cough/fever or a history of contact with positive COVID-19 patients. CONCLUSIONS: The seroprevalence of SARS-CoV-2 antibody was 13.5% among eligible blood donors, and hence the current eligibility criteria allow asymptomatic COVID-19 patients to donate blood. The seroprevalence was seen more in first time donors, suggesting that regular blood donors are safer. Additional risk factors related to lifestyle can be identified to ensure safety of transfusion during COVID-19 pandemic. S. Karger AG 2021-07-09 /pmc/articles/PMC8339022/ http://dx.doi.org/10.1159/000517456 Text en Copyright © 2021 by The Author(s) Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. |
spellingShingle | Research Article Raouf, May Rabeh, Mariem Kaur, Suminder Sharma, Ranjita Thottumkal, Nimmy Mohammed, Roukaya Seroprevalence of IgG Anti-SARS-CoV-2 among Voluntary Blood Donors in Dubai: Demographic and Risk Factors |
title | Seroprevalence of IgG Anti-SARS-CoV-2 among Voluntary Blood Donors in Dubai: Demographic and Risk Factors |
title_full | Seroprevalence of IgG Anti-SARS-CoV-2 among Voluntary Blood Donors in Dubai: Demographic and Risk Factors |
title_fullStr | Seroprevalence of IgG Anti-SARS-CoV-2 among Voluntary Blood Donors in Dubai: Demographic and Risk Factors |
title_full_unstemmed | Seroprevalence of IgG Anti-SARS-CoV-2 among Voluntary Blood Donors in Dubai: Demographic and Risk Factors |
title_short | Seroprevalence of IgG Anti-SARS-CoV-2 among Voluntary Blood Donors in Dubai: Demographic and Risk Factors |
title_sort | seroprevalence of igg anti-sars-cov-2 among voluntary blood donors in dubai: demographic and risk factors |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339022/ http://dx.doi.org/10.1159/000517456 |
work_keys_str_mv | AT raoufmay seroprevalenceofiggantisarscov2amongvoluntaryblooddonorsindubaidemographicandriskfactors AT rabehmariem seroprevalenceofiggantisarscov2amongvoluntaryblooddonorsindubaidemographicandriskfactors AT kaursuminder seroprevalenceofiggantisarscov2amongvoluntaryblooddonorsindubaidemographicandriskfactors AT sharmaranjita seroprevalenceofiggantisarscov2amongvoluntaryblooddonorsindubaidemographicandriskfactors AT thottumkalnimmy seroprevalenceofiggantisarscov2amongvoluntaryblooddonorsindubaidemographicandriskfactors AT mohammedroukaya seroprevalenceofiggantisarscov2amongvoluntaryblooddonorsindubaidemographicandriskfactors |